Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Integrated incremental immunoreactive insulin and connecting peptide responses to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respectively, were measured in 14 Type 2 (non-insulin-dependent) diabetic patients and 8 age- and weight-matched metabolically healthy control subjects. Differences between responses to oral and intravenous glucose administration are attributed to factors other than glucose itself (incretin effect). Despite higher glucose increases, immunoreactive insulin and connecting peptide responses after oral glucose were delayed in diabetic patients. Integrated responses were not significantly different between both groups. However, during "isoglycaemic" intravenous infusion, insulin and connecting peptide responses were greater in diabetic patients than in control subjects as a consequence of the higher glycaemic stimulus. The contribution of incretin factors to total insulin responses was 72.8 +/- 6.9% (100% = response to oral load) in control subjects and 36.0 +/- 8.8% in diabetic patients (p less than or equal to 0.05). The contribution to connecting peptide responses was 58.4 +/- 7.6% in control subjects and 7.6 +/- 14.5% (p less than or equal to 0.05) in diabetic patients. Ratios of integrated insulin to connecting peptide responses suggest a reduced (hepatic) insulin extraction in control subjects after oral as compared to intravenous glucose. This was not the case in diabetic patients. Immunoreactive gastric inhibitory polypeptide responses were not different between control subjects and diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“People with obesity and/or T2D have impaired incretin release ( Toft-Nielsen et al., 2001 ; Vilsbøll et al., 2001 ) and/or function ( Nauck et al., 1986 ; Muscelli et al., 2008 )”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Nauck et al., 1986
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 2×
“Thus the study of Perley and Kipnis [ 10 ] from 1967 does not - in the absence of C-peptide measurements - allow final conclusions about the incretin effect in Type 2 diabetic patients.”
BackgroundSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 5×
“In healthy young subjects, a clear dose-dependency of incretin effects after oral glucose has been observed [6].”
BackgroundResultInfluentialSelf-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2].”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Arguing against this explanation, intravenous isoproterenol [36] or glucagon [ 37 ] enhanced, rather than diminished, additional B cell secretory responses in Type 2 diabetic patients when plasma glucose levels had been elevated by glucose infusion up to the range employed in our study.”
ResultC-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
Polonsky, K. S., & Rubenstein, A. H. (1984) · Diabetes · doi:10.2337/diab.33.5.486 · Cited by 476 · cited 3×
“This conclusion must, however, remain speculative because of reservations regarding the "insulin to C-peptide ratio method" for estimating changes in (hepatic) insulin extraction [ 33 ].”
BackgroundMethodInfluentialTHE PLASMA INSULIN RESPONSE TO GLUCOSE INFUSION IN HEALTHY SUBJECTS AND IN DIABETES MELLITUS
Cerasi, E., & Luft, R. (1967) · Acta Endocrinologica · doi:10.1530/acta.0.0550278 · Cited by 371 · cited 2×
“The markedly reduced incretin effect found in our group with a more severe degree of Type 2 diabetes may simply be an expression of their impaired capacity to secrete insulin at an adequate rate [3, 4 ]. The glycaemic stimulus with plasma glucose values of -17mmol/1 (300mg/dl) may already have led to maximal B cell st…”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2 ].”
Background
Research works printed but not linked: 4
- Bloom SR (1975) GIP in diabetes (abstract). Diabetologia 11: 334
- WHO Expert Committee on Diabetes Mellitus, Second Report, Technical Report Series 646, WHO, Geneva, 1980
- Madison LL, Kaplan N (1958) The hepatic binding of I-131 labeled insulin in human subjects during a single transhepatic circulation. J Lab Clin Med 52: 927–932
- Ross SA, Brown JC, Dupre J (1974) Effects of Gastric Inhibitory Polypeptide on endocrine pancreas in normal and diabetic subjects. Diabetologia 10: 384 (Abstract)
Cited by
Items 201–300 of 1,001
Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT
He, Y., Wang, Y., Bullock, J. M., Deacon, C. F., Holst, J. J., Dunning, B. E., Ligueros‐Saylan, M., & Foley, J. E. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006299137 · Cited by 99
The role of glucagon on type 2 diabetes at a glance
Godoy-Matos, A. F. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-91 · Cited by 99
“insulinotropic incretin hormones GIP and GLP-1 account for <20% of postprandial insulin response [22],”
BackgroundGLP‐1: physiological effects and potential therapeutic applications
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 95
Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats
Huisamen, B., Genis, A., Marais, E., & Lochner, A. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6271-7 · Cited by 103
“We confirmed previous reports of lower GLP-1 levels in animal models of insulin resistance [16] as well as in type 2 diabetic patients [4] and showed that DPP4 therapy will elevate these levels, as also shown by others and summarized extensively [16, 32].”
BackgroundResultLiraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
Vilsbøll, T. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.231 · Cited by 95
“In patients with Type 2 diabetes mellitus, the incretin effect is greatly impaired and it is assumed that this may contribute to the inability of these patients to adjust their insulin secretion to their needs [4].”
BackgroundHayden, M. R., Patel, K., Habibi, J., Gupta, D., Tekwani, S. S., Whaley‐Connell, A. T., & Sowers, J. R. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.00024.x · Cited by 108
Gault, V. A., Flatt, P. R., & O'Harte, F. P. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01361-5 · Cited by 99
Immunoreactive Gastric Inhibitory Polypeptide*
KRARUP, T. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-1-122 · Cited by 96
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Michaliszyn, S. F., Mari, A., Lee, S., Bacha, F., Tfayli, H., Farchoukh, L., Ferrannini, E., & Arslanian, S. (2014) · Diabetes · doi:10.2337/db13-1951 · Cited by 92
“Moreover, the incretin effect, defined as a higher insulin response to oral than intravenous glucose at similar prevailing glucose concentrations, is found to be markedly reduced in adults with T2D (21,22), but similar in IGT (23,24), compared with NGT.”
MethodResultK-cells and Glucose-Dependent Insulinotropic Polypeptide in Health and Disease
Cho, Y. M., & Kieffer, T. J. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00004-7 · Cited by 110
Madsbad, S., Krarup, T., Deacon, C. F., & Holst, J. J. (2008) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e328302f414 · Cited by 93
Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes
Ravassa, S., Zudaire, A., Carr, R. D., & Díez, J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00885.2010 · Cited by 91
Newer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 111
Incretins and the development of type 2 diabetes
Meier, J. J., & Nauck, M. A. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0034-7 · Cited by 110
“The marked reduction in the incretin effect in patients with type 2 diabetes gave rise to speculations that defects in the secretion and action of GIP and GLP-1 might lead to the development of type 2 diabetes [ 18 ,63].”
BackgroundInfluentialSelf-citationLynn, F. C., Thompson, S. A., Pospisilik, J. A., Ehses, J. A., Hinke, S. A., Pamir, N., McIntosh, C. H. S., & Pederson, R. A. (2003) · The FASEB Journal · doi:10.1096/fj.02-0243fje · Cited by 91
Flint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91
Aulinger, B. A., Bedorf, A., Kutscherauer, G., de Heer, J., Holst, J. J., Göke, B., & Schirra, J. (2014) · Diabetes · doi:10.2337/db13-1455 · Cited by 92
“Ex(9-39)acetate was purchased as a lyophilized sterile powder at pharmaceutical grade from Bachem (Clinalfa Products, Läufelfingen, Switzerland).”
BackgroundMethodInfluentialDissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 91
Metwally, A. A., Perelman, D., Park, H., Wu, Y., Jha, A., Sharp, S. A., Celli, A., Ayhan, E. M., Abbasi, F., Gloyn, A. L., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01311-6 · Cited by 119
“The difference in C-peptide concentrations during the OGTT relative to the IIGI was quantified at 7 timepoints (0, 15, 30, 60, 90, 120 and 180 min) to reflect the period of maximal hyperglycaemia (Extended Data Fig.”
InfluentialJones, I. R., Owens, D. R., Luzio, S. D., Williams, S. E. I., & Hayes, T. M. (1989) · Diabetologia · doi:10.1007/bf00274255 · Cited by 101
“The antisera cross-react with a GIP [ 15-42 ] C-terminal fragment which is the region where amino acid differences between porcine and human GIP are found [15].”
Yabe, D., Kuroe, A., Lee, S., Watanabe, K., Hyo, T., Hishizawa, M., Kurose, T., Deacon, C. F., Holst, J. J., Hirano, T., et al. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00010.x · Cited by 90
Vardarli, I., Arndt, E., Deacon, C. F., Holst, J. J., & Nauck, M. A. (2014) · Diabetes · doi:10.2337/db13-0805 · Cited by 92
“In patients with type 2 diabetes, this incretin effect is impaired (2), mainly because diabetic b-cells no longer respond to GIP (3,4).”
BackgroundMethodSelf-citationGastrointestinal peptides and insulin secretion
Ebert, R., & Creutzfeldt, W. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030101 · Cited by 100
Self-citationNyholm, B., Walker, M., Gravholt, C. H., Shearing, P. A., Sturis, J., Alberti, K. G. M. M., Holst, J. J., & Schmitz, O. (1999) · Diabetologia · doi:10.1007/s001250051444 · Cited by 97
Højberg, P. V., Zander, M., Vilsbøll, T., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetologia · doi:10.1007/s00125-008-0943-x · Cited by 89
“Several investigators have shown that the incretin effect is attenuated in patients with type 2 diabetes, primarily because of a reduced insulinotropic effect of GIP, while the effect of GLP-1 is relatively more preserved [5–8].”
BackgroundJimenez‐Solem, E., Rasmussen, M. H., Christensen, M., & Knop, F. K. (2010) · PubMed · Cited by 89
Effect of gastric bypass surgery on the incretins
Laferrère, B. (2009) · Diabetes & Metabolism · doi:10.1016/s1262-3636(09)73458-5 · Cited by 90
“Some determinants of impaired insulin secretion in T2DM, such as glucose or lipid toxicity [3,4], likely improve as a result of weight loss per se.”
BackgroundInfluentialMeier, J. J., Deacon, C. F., Schmidt, W. E., Holst, J. J., & Nauck, M. A. (2007) · Diabetologia · doi:10.1007/s00125-007-0598-z · Cited by 102
“Unlike healthy volunteers, patients with type 2 diabetes show only small differences in insulin secretion between oral and intravenous glucose administration [14].”
BackgroundSelf-citationDiabetes remission after bariatric surgery: is it just the incretins?
Laferrère, B. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.143 · Cited by 88
Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line
Simpson, A. K., Ward, P. S., Wong, K. Y., Collord, G. J., Habib, A. M., Reimann, F., & Gribble, F. M. (2007) · Diabetologia · doi:10.1007/s00125-007-0750-9 · Cited by 88
“Together with glucose-dependent insulinotrophic peptide (GIP), it is responsible for up to 50% of normal insulin release following a meal [1].”
BackgroundInfluentialRecent Developments in Alpha-Glucosidase Inhibitors for Management of Type-2 Diabetes: An Update
Bashir, U., Sharma, N., Satija, S., Mehta, M., Vyas, M., Khatik, G. L., Khurana, N., Hansbro, P. M., Williams, K. A., & Dua, K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190717104547 · Cited by 92
Naito, T., Kuma, A., & Mizushima, N. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.456228 · Cited by 87
“Insulin secretion was only slightly induced by glucose injection, which may reflect that incretins (intestinal hormones) are important for feeding-induced insulin secretion (31, 32).”
BackgroundJunker, A. E., Gluud, L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12462 · Cited by 88
Meier, J. J., Gallwitz, B., Kask, B., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s220 · Cited by 85
“In contrast, a marked reduction of the incretin effect characterizes patients with type 2 diabetes (4).”
BackgroundSelf-citationDPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Deacon, C. (2008) · Frontiers in Bioscience · doi:10.2741/2799 · Cited by 80
DPP4 Inhibitors: a new approach in diabetes treatment
Doupis, J., & Veves, A. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0076-1 · Cited by 95
Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly
Gentilcore, D., Bryant, B., Wishart, J. M., Morris, H. A., Horowitz, M., & Jones, K. L. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.05.019 · Cited by 87
Novel agents for the treatment of type 2 diabetes
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.100 · Cited by 83
Hare, K. J., Vilsbøll, T., Holst, J. J., & Knop, F. K. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00700.2009 · Cited by 84
“1 and Table 2), reflecting an intact incretin effect of 45 4% (19, 21).”
BackgroundMethodPeptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes
Deacon, C. F. (2018) · Peptides · doi:10.1016/j.peptides.2017.10.011 · Cited by 89
“the greater insulin response to oral – as opposed to isoglycaemic intravenous infusion of – glucose) was known to be impaired in T2DM [11], so it was of particular interest to find that GLP-1 was insulinotropic in patients with T2DM, and could normalise fasting glucose levels when given intravenously [12].”
InfluentialKuhre, R. E., Albrechtsen, N. J. W., Hartmann, B., Deacon, C. F., & Holst, J. J. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.12.006 · Cited by 97
Glucagon-Like Peptide-1-Based Therapies for the Treatment of Type 2 Diabetes Mellitus
Gallwitz, B. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504060-00005 · Cited by 93
Ma, J., Pilichiewicz, A. N., Feinle‐Bisset, C., Wishart, J. M., Jones, K. L., Horowitz, M., & Rayner, C. K. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03496.x · Cited by 82
Hinke, S. A., Manhart, S., Pamir, N., Demuth, H.-U., Gelling, R. W., Pederson, R. A., & McIntosh, C. H. S. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(01)00181-9 · Cited by 89
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
“While GIP loses its insulinotropic effect in T2D with chronic hyperglycemia, GLP-1 is still able to stimulate insulin secretion (28, 29).”
BackgroundEvolution of Exenatide as a Diabetes Therapeutic
Bhavsar, S., Mudaliar, S., & Cherrington, A. (2013) · Current Diabetes Reviews · doi:10.2174/157339913805076472 · Cited by 81
Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor
Willard, F. S., & Sloop, K. W. (2012) · Experimental Diabetes Research · doi:10.1155/2012/470851 · Cited by 79
“These efforts provided much of the foundation for pharmaceutical development of the GLP-1 receptor peptide agonists, exenatide and liraglutide, as novel medicines for patients suffering from T2DM.”
BackgroundInfluentialAutomated closed-loop control of diabetes: the artificial pancreas
Kovatchev, B. (2018) · Bioelectronic Medicine · doi:10.1186/s42234-018-0015-6 · Cited by 80
Cotero, V. E., Graf, J. F., Miwa, H., Hirschstein, Z., Qanud, K., Huerta, T. S., Tai, N., Ding, Y., Jimenez-Cowell, K., Tomaio, J. N., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00870-w · Cited by 87
An overview of the pharmacokinetics, efficacy and safety of liraglutide
Bode, B. W. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.12.015 · Cited by 94
“[2] Nauck M, Stöckmann F, Ebert R, Creutzfeldt W.”
BackgroundWhat Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
Kuhre, R. E., Deacon, C. F., Holst, J. J., & Petersen, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694284 · Cited by 78
“They have also shown that the incretin effect is reduced in humans living with type-2-diabetes (152), and that this is due to loss of GIP’s (153, 154), but not GLP-1’s, insulinotropic activity (155– 157).”
BackgroundGunnerud, U. J., Heinzle, C., Holst, J. J., Östman, E. M., & Björck, I. M. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044731 · Cited by 81
An Integrated Glucose‐Insulin Model to Describe Oral Glucose Tolerance Test Data in Type 2 Diabetics
Jauslin, P. M., Silber, H. E., Frey, N., Gieschke, R., Simonsson, U. S. H., Jorga, K. M., & Karlsson, M. O. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007302168 · Cited by 84
“As a further means of validation, the results of this simulation study were then compared with actual patterns of experimental data obtained in a study by Nauck et al.(17)”
MethodResultß‐cell function and anti‐diabetic pharmacotherapy
Prato, S. D., Bianchi, C., & Marchetti, P. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.770 · Cited by 108
“reduced [78].”
Meier, J. J., Gallwitz, B., Askenas, M., Vollmer, K., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1863-7 · Cited by 87
“A reduced incretin effect is characteristic of patients with type 2 diabetes [6], and two different defects in the”
BackgroundSelf-citationGenetic determinants and molecular pathways in the pathogenesis of Type 2 diabetes
Jin, W., & Patti, M.-E. (2009) · Clinical Science · doi:10.1042/cs20080090 · Cited by 78
Aso, Y., Ozeki, N., Terasawa, T., Naruse, R., Hara, K., Suetsugu, M., Takebayashi, K., Shibazaki, M., Haruki, K., Morita, K., et al. (2011) · Translational research · doi:10.1016/j.trsl.2011.09.005 · Cited by 83
“In patients with type 2 diabetes, the effects of these incretins are impaired, resulting in marked postprandial hyperglycemia.(3,4) Dipeptidyl peptidase 4 (DPP-4) is a 110-kD cell surface type II transmembrane protein that displays catalytic activity as a serine protease.”
BackgroundFritsche, A., Stefan, N., Hardt, E., Häring, H., & Stümvoll, M. (2000) · Diabetologia · doi:10.1007/s001250051461 · Cited by 78
Incretins and other peptides in the treatment of diabetes
Todd, J. F., & Bloom, S. R. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.02071.x · Cited by 76
Ørskov, J. J. H. (2001) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/clb.61.234.75.85 · Cited by 71
The Incretin Notion and its Relevance to Diabetes
Habener, J. F. (1993) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30135-x · Cited by 89
Vilsbøll, T., Agersø, H., Lauritsen, T. L. B., Deacon, C. F., Aaboe, K., Madsbad, S., Krarup, T., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.007 · Cited by 81
Incretin physiology and pathophysiology from an A sian perspective
Cho, Y. M. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12305 · Cited by 80
Advances in therapy for type 2 diabetes: GLP–1 receptor agonists and DPP–4 inhibitors
Kennedy, L., & Davidson, J. A. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.05 · Cited by 75
Jones, I. R., Owens, D. R., Moody, A. J., Luzio, S. D., Morris, T., & Hayes, T. M. (1987) · Diabetologia · doi:10.1007/bf00296993 · Cited by 82
“[33] who described a reduced incretin effect in Type 2 diabetic patients compared with normal control subjects.”
BackgroundSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
“The incretin effect is impaired in patients with type 2 diabetes, probably because of resistance to the incretin hormones [8,27], thereby reducing oral glucose disposal [8].”
BackgroundRecent advances in incretin‐based therapies
Russell-Jones, D. L., & Gough, S. C. L. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04483.x · Cited by 83
Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes
LEE, S., YABE, D., NOHTOMI, K., TAKADA, M., MORITA, R., SEINO, Y., & HIRANO, T. (2010) · Endocrine Journal · doi:10.1507/endocrj.k09e-269 · Cited by 73
“the impairment of these incretin effects is a well known feature in patients with type 2 diabetes mellitus (t2Dm) [1-4].”
Backgroundvan Genugten, R. E., van Raalte, D. H., & Diamant, M. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01473.x · Cited by 73
“that following oral ingestion of glucose, because of the secretion of the gut-derived incretin hormones, the increase in plasma insulin response is twofold to threefold greater than is the case when the same level of hyperglycaemia is produced by intravenous administration of glucose [7].”
BackgroundInfluentialLixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
Christensen, M., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2009) · PubMed · Cited by 84
Henkel, E., Menschikowski, M., Koehler, C., Leonhardt, W., & Hanefeld, M. (2005) · Metabolism · doi:10.1016/j.metabol.2005.03.024 · Cited by 81
“It has been noted that the glucose-induced insulin response is greater after an oral load as compared with an IV glucose injection because of the effect of incretins [14].”
BackgroundWoerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J. (2012) · Diabetes · doi:10.2337/db11-1701 · Cited by 73
“Plasma glucagon concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A…”
InfluentialFrías, J. P. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1830759 · Cited by 70
Emerging treatment options for type 2 diabetes
Piya, M. K., Tahrani, A. A., & Barnett, A. H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03711.x · Cited by 72
Sonne, D. P., Hansen, M., & Knop, F. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0154 · Cited by 75
Incretin Effect After Oral Amino Acid Ingestion in Humans
Lindgren, O., Pacini, G., Tura, A., Holst, J. J., Deacon, C. F., & Ahrén, B. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3865 · Cited by 77
“This study examined whether an incretin effect exists after oral ingestion of amino acids, as it has previously been shown after oral glucose and oral lipids (2,4).”
BackgroundAdetunji, O., Kalra, S., Baruah, M., Sahay, R., Unnikrishnan, A., & Uppal, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.176351 · Cited by 71
“reported reduced incretin effects in patients with type 2 diabetes.[5] In 1993, they demonstrated that, in patients with poorly controlled type 2 diabetes, a single exogenous infusion of GLP‐1 increased insulin levels in a glucose‐dependent manner normalizing fasting hyperglycemia.”
BackgroundUbiquitination is involved in glucose-mediated downregulation of GIP receptors in islets
Zhou, J., Livak, M. F. A., Bernier, M., Muller, D. C., Carlson, O. D., Elahi, D., Maudsley, S., & Egan, J. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00070.2007 · Cited by 73
“In type 2 diabetes there is a functional impairment of the insulinotropic effect of GIP (40, 41).”
BackgroundChaikomin, R., Doran, S., Jones, K. L., Feinle-Bisset, C., O'Donovan, D., Rayner, C. K., & Horowitz, M. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00099.2005 · Cited by 71
“Although we did not study type 2 patients, it is well documented that first phase insulin secretion is impaired in this group, as is the incretin effect (19).”
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Jensen, D. H., Aaboe, K., Henriksen, J. E., Vølund, A., Holst, J. J., Madsbad, S., & Krarup, T. (2012) · Diabetologia · doi:10.1007/s00125-012-2459-7 · Cited by 76
“We examined first-degree relatives of individuals with type 2 diabetes and measured the incretin effect before and after dexamethasone [5, 14].”
BackgroundThe β Cell in Diabetes: Integrating Biomarkers With Functional Measures
Kahn, S. E., Chen, Y., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab021 · Cited by 80
“These 2 different routes of administration also helped delineate the incretin concept that is characterized by a greater β-cell response when glucose is ingested than when matched glucose levels are achieved with intravenous glucose infusion (509-511).”
BackgroundDeacon, C. F. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00765.x · Cited by 70
Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases
Mascolo, A., Rafaniello, C., Sportiello, L., Sessa, M., Cimmaruta, D., Rossi, F., & Capuano, A. (2016) · Drug Safety · doi:10.1007/s40264-016-0399-8 · Cited by 71
Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery
Svane, M. S., Bojsen-Møller, K. N., Nielsen, S., Jørgensen, N. B., Dirksen, C., Bendtsen, F., Kristiansen, V. B., Hartmann, B., Holst, J. J., & Madsbad, S. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00471.2015 · Cited by 72
“The incretin effect is severely impaired in type 2 diabetes (35) but is also reduced in obese people with NGT (28), which is possibly due to a subtle -cell defect and attenuated effects of GLP-1 and GIP (14, 28, 37).”
BackgroundCurrent Treatment Options for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Beaton, M. D. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/725468 · Cited by 75
Trahair, L. G., Horowitz, M., Rayner, C. K., Gentilcore, D., Lange, K., Wishart, J. M., & Jones, K. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2583 · Cited by 69
“The so-called incretin hormones, GLP-1 and GIP, account for up to 70% of postprandial insulin secretion (19).”
BackgroundThe cephalic phase of insulin release is modulated by IL-1β
Wiedemann, S. J., TRIMIGLIOZZI, K. A., Dror, E., Meier, D. T., Molina‐Tijeras, J. A., Rachid, L., Foll, C. L., Magnan, C., Schulze, F., Stawiski, M., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.001 · Cited by 72
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Holst, J. J., & Krarup, T. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.07.002 · Cited by 73
Liraglutide Effect and Action in Diabetes (LEAD™) trial
Madsbad, S. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.4.2.119 · Cited by 77
Microbial Regulation of Glucose Metabolism and Insulin Resistance
Crommen, S., & Simon, M.-C. (2017) · Genes · doi:10.3390/genes9010010 · Cited by 65
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update)
Gallwitz, B. (2007) · Drugs of Today · doi:10.1358/dot.2007.43.11.1157620 · Cited by 66
Preservation of β-cell function by targeting β-cell mass
DEKONING, E., Bonner‐Weir, S., & Rabelink, T. J. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.02.001 · Cited by 84
Effects of meal size and composition on incretin, α-cell, and β-cell responses
Rijkelijkhuizen, J. M., McQuarrie, K., Girman, C. J., Stein, P. P., Mari, A., Holst, J. J., Nijpels, G., & Dekker, J. M. (2009) · Metabolism · doi:10.1016/j.metabol.2009.07.039 · Cited by 77
PPARβ/δ Activation Induces Enteroendocrine L Cell GLP-1 Production
Daoudi, M., Hennuyer, N., Borland, M. G., Touche, V., Duhem, C., Gross, B. S., Caiazzo, R. J., Kerr-Conte, J. A., Pattou, F. N., Peters, J. M., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.045 · Cited by 79
Signaling Mechanisms Underlying the Release of Glucagon-Like Peptide 1
Reimann, F., Ward, P. S., & Gribble, F. M. (2006) · Diabetes · doi:10.2337/db06-s010 · Cited by 68
“Two hormones, glucagon-like peptide-1 (GLP-1) and glucosedependent insulinotropic peptide (GIP), are thought to underlie the incretin effect, which in healthy individuals, accounts for up to 50% of the normal insulin release after a meal (3,4).”
BackgroundRussell, S. (2012) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-012-9729-9 · Cited by 77
In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update
Kury, L. T. A., Abdoh, A., Ikbariah, K., Sadek, B. S., & Mahgoub, M. (2021) · Molecules · doi:10.3390/molecules27010182 · Cited by 79
Metadata
- Authors
- Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W.
- ORCID
- Nauck, M.
- Venue
- Diabetologia
- Published
- 1986-01
- Volume
- 29
- Issue
- 1
- Pages
- 46-52
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2054564814
- Cited by
- 1,307
- References
- 40
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 45 · 2023: 38 · 2022: 53 · 2021: 46 · 2020: 44 · 2019: 60 · 2018: 41 · 2017: 47 · 2016: 65 · 2015: 63 · 2014: 82 · 2013: 86 · 2012: 74
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, insulin secretion, C-peptide, glucose-dependent insulinotropic polypeptide, oral glucose tolerance, intravenous glucose infusion, hepatic insulin extraction, immunoreactive insulin
- MeSH terms
- Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Humans, Infusions, Parenteral, Insulin, Male, Middle Aged, Pancreas
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.